Abstract
Hypertensive crisis (HC) is an emergency health condition which requires an effective management strategy. Over the years, various researchers have developed captopril based fast-dissolving formulations to manage HC; however, primarily, the question of personalisation remains unaddressed. Moreover, commercially these formulations are available as in fixed-dose combinations or strengths, so the titration of dose according to patient’s prerequisite is challenging to achieve. The recent emergence of 3D printing technologies has given pharmaceutical scientists a way forward to develop personalised medicines keeping in view patients individual needs. The current project, therefore, is aimed at addressing the limitations as mentioned above by developing fast-dissolving captopril tablets using 3D printing approach. Captopril unloaded (F1) and loaded (F2-F4) filaments were successfully produced with an acceptable drug loading and mechanical properties. Various captopril formulations (F2–F4) were successfully printed using fused deposition modelling technique. The results revealed that the formulations (F2 and F3) containing superdisintegrant had a faster extent of dissolution and in-vivo findings were endorsing these results. The present study has successfully exhibited the utilisation of additive manufacturing approach to mend the gap of personalisation and manufacturing fast-dissolving captopril 3D printed tablets. The procedure adopted in the present study may be used for the development of fused deposition modelling (FDM) based fast-dissolving 3D printed tablets.
Highlights
Hypertension is a public-health challenge due to its high prevalence and concomitant risks, including kidney and cardiovascular complications [1,2]
Differential Scanning Calorimetry (DSC) thermograms were acquired for captopril loaded filaments (F2–F4) to investigate any interactions and itofisFilaments confirmed that there was no crystalline drug evident in the
DSC thermograms were acquired for captopril loaded filaments (F2-F4) to investigate
Summary
Hypertension is a public-health challenge due to its high prevalence and concomitant risks, including kidney and cardiovascular complications [1,2]. It has been identified as a leading cause of mortality and the third-ranked factor for DALY (disability-adjusted life-years) worldwide [1,3,4,5]. The global burden and prevalence of hypertension are rising over time driven by changes in lifestyle, population growth and ageing It is present among one billion of the world population and is Polymers 2020, 12, 3057; doi:10.3390/polym12123057 www.mdpi.com/journal/polymers. It is reported that approximately 1% of the patients with hypertension develop hypertensive crisis at some point during their life span, men are approximately affected two times more frequently than women [10,11]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
